Synopsis
Detect sight-threatening diabetic retinal disease before vision is lost, distinguish screening from diagnostic eye care, and coordinate timely ophthalmic treatment while improving systemic risk safely.
- Diabetic eye screening detects retinal change in people who may still see normally; it does not replace a routine sight test or assessment of new visual symptoms.
- The English programme invites eligible people with diabetes from age 12, excluding gestational diabetes alone; pathways and intervals differ across UK nations, so verify the local programme.
- Background non-proliferative disease reflects microaneurysms, haemorrhages and exudates, whereas proliferative disease is defined by retinal or disc neovascularisation and threatens vitreous haemorrhage and tractional detachment.
- Diabetic macular oedema threatens central vision through retinal thickening or fluid near the fovea and may require optical coherence tomography even when a photograph suggests only subtle change.
- Referable screening findings trigger diagnostic ophthalmology assessment; a screening grade is a risk signal, not the final treatment diagnosis.
- Panretinal photocoagulation remains core treatment for proliferative diabetic retinopathy, while anti-VEGF, focal or grid laser and selected steroid therapy are used for macular oedema according to NICE and ophthalmic assessment.
- Pregnancy and rapid improvement of long-standing hyperglycaemia can temporarily accelerate retinopathy, so arrange surveillance rather than withholding necessary glucose treatment.
- Control of blood pressure, glucose, kidney disease, lipids and smoking risk reduces progression, but systemic optimisation never substitutes for indicated laser, injection or vitreoretinal surgery.
- New eye symptoms bypass routine screening: screening intervals are designed for asymptomatic surveillance and are unsafe as an emergency waiting list.
Key red flags
New vessels at the disc or elsewhere, preretinal haemorrhage, vitreous haemorrhage or fibrous proliferation signals high risk of severe sight loss and needs timely ophthalmic treatment.
Blurred or distorted central vision and difficulty reading may accompany centre-involving retinal thickening, although optical coherence tomography can find clinically important oedema before prominent symptoms.
Sudden painless haze, cobwebs, spots or marked loss of vision in an eye with proliferative disease can represent bleeding from fragile neovascular tissue and warrants urgent assessment.
A curtain, missing field, distortion or progressive visual loss may reflect fibrovascular traction threatening or involving the macula; vitreoretinal review must not await screening recall.
Increasing pain, redness, photophobia and reduced vision after an intravitreal injection is an ophthalmic emergency because infectious endophthalmitis can destroy vision rapidly.
Investigation priorities
Screen eligible asymptomatic people for diabetic retinal and macular abnormalities.
Management branches
Eligible person with diabetes who has no acute visual symptom requiring diagnostic assessment.
- Confirm enrolment in the correct national programme, current contact details, accessibility needs and whether pregnancy or previous eye treatment changes the standard recall route.
- Explain dilation, temporary blur and driving implications; obtain quality-assured retinal photographs and ensure ungradable images enter the alternative assessment pathway.
- Communicate the grade and next step in understandable language, distinguishing routine recall, closer surveillance and referral to hospital eye services.
- Use non-attendance as a safety problem: explore transport, language, disability, fear and deprivation barriers and apply local failsafe procedures rather than silently closing the episode.